source
- AI-focused biotech firms drive biopharma toward a 'fail-fast' drug development modelAI is quickly becoming a central force in drug development as tech capital pours into biopharma, reshaping how new medicines are discovered. Tyrone Lam, chief business officer at GATC Health, says…
- Pfizer’s former chemistry whiz debuts Khartis Therapeutics with $95M for thyroid eye disease pillThree years after Robert Hoffman sold XinThera to Gilead, the veteran Pfizer chemist has unveiled his latest venture.Fierce Biotech · 1d ago↗ source
- Scholar Rock pulls Indiana fill-finish plant from SMA therapy filing after FDA flags violations